2025年5月17~20日，欧洲心脏病学会心力衰竭协会年会暨世界急性心力衰竭大会（ESC-HFA 2025）即将在塞尔维亚贝尔格莱德盛大召开。ESC-HFA 2025是欧洲心脏病学会-心衰协会（ESC-HFA）的年度会议，旨在通过更好地预防、诊断和治疗心衰，来提高患者的生活质量和寿命。

 

近日，会议官网公布了本届大会的初步日程，在Late-Breaking Science专场将公布62项重磅研究结果。让我们先睹为快吧！

 

Hottest trials and trial updates (1)

最热门试验和试验更新（1）

当地时间：5月17 日10:45 ~12:15

 

1.FINEARTS-HF: Blinded drug withdrawal

FINEARTS-HF试验：盲法药物撤药

讲者: Muthiah Vaduganathan

 

2.FAIR-HF2 DZHK05: Efficacy of ferric carboxymaltose in heart failure and iron deficiency stratified by transferrin saturation

FAIR-HF2 DZHK05试验：羧基麦芽糖铁在按铁蛋白水平分层的心衰和铁缺乏患者中的疗效

讲者：Stefan Anker

 

3.FUTURE-HF: Long-term safety, accuracy, and utility of a novel implantable IVC sensor for remote HF management

FUTURE-HF试验：用于远程心衰管理的新型下腔静脉（IVC）传感器的长期安全性、准确性和实用性
讲者: Kevin Damman

 

4.SOGALDI-PEF: SOdium-Glucose cotransporter 2 inhibitor with and without an ALDosterone AntagonIst for heart failure with preserved ejection fraction

SOGALDI-PEF试验：射血分数保留的心衰（HFpEF）患者使用钠-葡萄糖协同转运蛋白-2抑制剂（SGLT2i）联合或不联合醛固酮拮抗剂的疗效和安全性

讲者: Joao Pedro Ferreira 

 

5.PRAISE-HFrEF: Glucagon-like peptide-1 receptor agonism in heart failure with reduced ejection fraction and obesity

PRAISE-HFrEF试验：合并肥胖的射血分数降低的心衰（HFrEF）患者，进行胰高血糖素样肽-1受体激动剂（GLP-1RA）治疗的疗效

讲者: Varun Sundaram

 

6.HELIOS-B: Vutrisiran reduces all-cause mortality

HELIOS-B试验：Vutrisiran可降低转甲状腺素蛋白淀粉样变心肌病（ATTR-CM）患者的全因死亡率

讲者: Marianna Fontana 

 

7.CRISPR gene editing with nexiguran ziclumeran in ATTR cardiomyopathy: treatment effect in hereditary vs. wild-type disease

遗传型和野生型ATTR-CM进行‌Nexiguran Ziclumeran（一种基于CRISPR/Cas9基因编辑疗法的创新药物）治疗的疗效对比

讲者：Marianna Fontana 

 

Late-breaking science: diagnostic methods and assessment

最新科学研究：诊断方法和评估策略

当地时间：5月17 日13:45 ~14:45

 

1.Heart failure screening using the "EPOF" symptom questionnaire and fingerstick NT-proBNP test

使用“EPOF”症状问卷和指尖血NT-proBNP测试进行心衰筛查

讲者：Emmanuelle Berthelot 

 

2.The HFpEF-ABA, H2FPEF, and HFA-PEFF scores and outcomes in individuals with HFpEF: a participant-level pooled analysis of 5 large-scale randomized clinical trials

5项大规模随机临床试验的个体水平汇总分析：HFpEF患者使用HFpEF-ABA 评分、H2FPEF评分、或HFA-PEFF评分进行评估与结局差异

讲者：John Ostrominski 

 

3.Predictors of diagnostic discrepancy in heart failure with preserved ejection fraction between supine and upright exercise right heart catheterization

HFpEF患者进行仰卧位与直立位运动右心导管检查诊断差异的预测因素

讲者：Sergio Caravita

 

4.Pulmonary capillary wedge pressure measures at rest and during exercise: a comparison of supine and upright positions

静息状态及运动时的肺毛细血管楔压测量：仰卧位 vs直立位

讲者：Veraprapas kittipibul

 

5.Implementing an AI-ECG based algorithm to screen for left ventricular dysfunction in Kenya: a prospective cohort study

一项前瞻性队列试验：在肯尼亚应用基于算法的AI-ECG筛查左心室功能障碍

讲者：Ambarish Pandey

 

6.Liver stiffness as a non-invasive tool to assess central venous pressure: a pilot validation study in patients with heart failure or low ejection fraction

在HFrEF患者中进行的初步验证试验：肝脏硬度值可作为评估中心静脉压的非侵入性工具

讲者: Nicolas Girerd

 

Late-breaking science in heart failure, cardiomyopathies, pulmonary hypertension and valvular heart disease

最新科学研究：心力衰竭、心肌病、肺动脉高压和心脏瓣膜病

当地时间：5月17 日16:00 ~17:00

 

1.Safety and tolerability of a 5 mg starting dose of vericiguat among patients with heart failure: the VELOCITY study

VELOCITY试验：5 mg起始剂量维立西呱在心衰患者中应用的安全性和耐受性

讲者： Stephen Greene

 

2.Cardiopulmonary exercise testing as a novel endpoint in clinical trials on ATTR amyloid cardiomyopathy

心肺运动试验作为ATTR-CM临床试验中的新型事件终点

讲者：Aldostefano Porcari

 

3.Efficacy and safety of aficamten in patients with obstructive hypertrophic cardiomyopathy and mild symptoms

症状轻微的梗阻性肥厚型心肌病患者使用Aficamten的有效性和安全性

讲者：Iacopo Olivotto

 

4.Pulmonary artery denervation clinical study using the gradient denervation system in heart failure patients with pulmonary hypertension group 2

在合并心衰的2型肺动脉高压患者中，应用梯度去神经支配系统进行经皮肺动脉去神经术（PADN）

讲者：Julio Nunez Villota

 

5.Hemodynamic effects of TX45 , a long-acting Fc-relaxin fusion, in Group 2 pulmonary hypertension patients

长效Fc-松弛素融合蛋白TX45对2型肺动脉高压患者的血流动力学影响

讲者：Anthony Muslin

 

6.Impact of dapagliflozin in quality of life of patients with aortic stenosis undergoing transcatheter aortic valve implantation

达格列净对接受经导管主动脉瓣植入术（TAVI）的主动脉瓣狭窄患者生活治疗的影响

讲者：Clara Bonanad Lozano

 

Late-breaking science: screening for heart failure and prognostic models

最新科学研究：心力衰竭的筛查及预后模型

当地时间：5月18日08:30~09:30

 

1.Predicting heart failure events in patients with persistent left ventricular dysfunction following acute myocardial infarction: Insights from the WICD-MI study

来自WICD-MI试验的见解：预测急性心梗后持续性左心室功能障碍患者的心衰事件风险

讲者：Mathieu Echivard

 

2.Decentralized community-based rapid cardiac ultrasound triage for early heart failure detection using a hub-and-spoke model: findings from Heart2Miss initiative

Heart2Miss倡议的试验结果：采用Hub-and-Spoke（中心辐射模式）的基于社区的分散式快速心脏超声分诊在早期心衰检测中的疗效

讲者：Diana Foo

 

3.Validation of a novel, non-invasive system for remote monitoring of left ventricular filling pressure in heart failure patients

在心衰患者中验证一种用于左心室充盈压远程监测的新型无创系统的疗效

讲者：Allan Bohm

 

4.Positive predictive value of a dynamic multiparameter heart failure risk score to identify worsening heart failure: primary results from the personalized therapy study

个性化治疗研究的主要结果：利用动态多参数心衰风险评分识别心衰恶化的阳性预测值

讲者：Charles Love

 

5.Impact of rurality and travel distance on the effectiveness of remote patient management in patients with heart failure: a pre-specified analysis of the randomised controlled TIM-HF2 trial

TIM-HF2随机对照试验预先指定的分析：乡村和旅行距离对心衰患者远程管理有效性的影响

讲者：Stefan Stoerk

 

6.Prognostic value of heart failure stratification and cardiologist follow-up in a nationwide cohort of 600,000+ patients

超60万例患者的全国性队列试验：心衰分层和心脏专科医生随访的预后价值

讲者：Guillaume Baudry

 

Hottest trials and trial updates (2)

最热门试验和试验更新（2）

当地时间：5月18 日10:45~12:15

 

1.DIGIT­HF: Baseline characteristics compared to recent trials in heart failure with reduced ejection fraction

DIGIT-HF试验：与近期HFrEF试验相比的基线特征

讲者：Udo Bavendiek

 

2.CIRRUS­HCM: A multiple-dose phase 2 study of safety, tolerability, and effects on hemodynamics and functional capacity of the novel cardiac sarcomere modulator EDG-7500 in hypertrophic cardiomyopathy

CIRRUS-HCM 2期多剂量试验：新型心肌肌节调节剂EDG-7500在肥厚型心肌病中的安全性、耐受性，以及对血流动力学和功能能力的影响

讲者：Anjali Owens

 

3.SEQUOIA­HCM: Effect of aficamten treatment on patients with hypertrophic obstructive cardiomyopathy by geographical region

SEQUOIA-HCM试验：在不同区域，aficamten治疗对梗阻性肥厚型心肌病患者的影响

讲者：Caroline Coats

 

4.GLADIATOR: The effects of geranylgeranylacetone in patients with HFpEF

GLADIATOR试验：替普瑞酮对HFpEF患者的影响
讲者：Gerhard Hendrik Dirk Voordes

 

5.EASY-STOP: Home urinary sodium monitoring for personalized diuretic titration in heart failure

EASY-STOP试验：针对心衰患者个体化利尿剂滴定的居家尿钠监测

讲者：Evelyne Meekers

 

6.HELP­AHF: optimal target of PEEP in mechanically ventilated patients with AHF

HELP-AHF试验：急性心衰（AHF）患者进行机械通气的呼气终末正压（PEEP）的最佳目标

讲者：Min-Seok Kim

 

7.PREFER­HF: Effects intravenous iron or oral iron therapy compared to placebo in HFpEF with iron deficiency anemia

PREFER-HF试验：与安慰剂相比，静脉补铁或口服补铁治疗对合并缺铁性贫血的HFpEF患者的影响
讲者：Jose Luis Morales Rull

 

Late-breaking clinical trials in chronic heart failure

最新科学研究：慢性心衰

当地时间：5月18日13:45 ~ 14:45

 

1.Safety and tolerability of diuretics withdrawal in patients with heart failure with reduced ejection fraction. REDICAE trial

REDICAE试验：HFrEF患者停用利尿剂的安全性和耐受性

讲者：Jesus Alberto Torres Zamudio

 

2.Oral iron supplementation with ferric maltol improves iron deficiency anaemia in patients with chronic heart failure

口服麦芽酚铁补充剂可改善慢性心衰患者的缺铁性贫血

讲者：Tibor Kempf

 

3.Gene therapy for heart failure with preserved ejection fraction

HFpEF患者进行基因疗法治疗

讲者：Marat Fudim

 

4.NAN-CS101: A first-in-human Phase 1 open-label dose-escalation study of AB-1002 gene therapy for the treatment of NYHA class III heart failure

NAN-CS101试验：AB-1002基因疗法治疗NYHA III期心衰患者的首次人体1期开放标签剂量递增研究

讲者：Roger J Hajjar

 

5.Finerenone on arterial stiffness and cardiorenal biomarkers in patients with type 2 diabetes and chronic kidney disease: a randomized placebo-controlled mechanistic trial (FIVE-STAR)

FIVE-STAR随机、安慰剂对照机制研究：非奈利酮对2型糖尿病合并慢性肾脏病患者动脉僵硬度及心肾生物标志物的影响

讲者：Atsushi Tanaka

 

6.Cardio-microcurrent device for chronic heart failure: results from the C-MIC II randomized controlled trial

C-MIC II期随机对照试验：心脏微电流装置在进行慢性心衰治疗中的疗效和安全性

讲者：Stefan Anker

 

Registries and clinical trials: new onset and chronic heart failure

注册和临床试验：新发和慢性心力衰竭

当地时间：5月18日 16:00~17:00

1.Primary results of TITRATE-HF: 1-year continuous GRMT implementation, prognosis, and LVEF improvement in de novo heart failure with reduced ejection fraction

TITRATE-HF试验的主要结果：在新诊断的HFrEF患者中，实施1年的持续GRMT对患者预后和LVEF改善的影响

讲者：Jasper Brugts

 

2.Sudden cardiac arrest in patients with newly diagnosed NICM or MI/CAD - nationwide analysis of >19.000 patients with a WCD

对＞1.9万佩戴穿戴式心脏除颤仪（WCD）患者的全国性分析：新诊断为非缺血性心肌病（NICM）或心梗/冠心病患者的心脏骤停情况

讲者：Johann Bauersachs

 

3.Digoxin lowers pulmonary artery pressures and heart rate in patients with heart failure and reduced ejection fraction

地高辛可降低HFrEF患者的肺动脉压力和心率

讲者：Joann Lindenfeld

 

4.Increased perirenal adipose tissue thickness is associated with autonomic dysfunction and reduced CGRP in patients with HFpEF: a prospective observational study

一项前瞻性观察性试验：肾周脂肪厚度增加与HFpEF患者的自主神经功能障碍及降钙素基因相关肽（CGRP）减少相关

讲者：Onur Can Polat

 

5.Impact of M-TEER on health status in patients with moderate-to-severe functional mitral regurgitation and heart failure: results from RESHAPE-HF2

RESHAPE-HF2试验结果：经导管二尖瓣缘对缘修复术（M-TEER）对中重度功能性二尖瓣反流合并心衰患者健康状况的影响

讲者：Javed Butler

 

6.Survival outcomes in younger patients with advanced heart failure: a comparative analysis of HeartMate 3 LVAD and heart transplant using MOMENTUM 3 and UNOS registry data

应用MOMENTUM 3和UNOS注册数据，对比HeartMate 3 LVAD和心脏移植对年轻晚期心衰患者生存结局的影响

讲者：Nir Uriel

 

Late-breaking science in acute heart failure

最新科学试验：急性心力衰竭

当地时间：5月19日 08:30~09:30

 

1.Kidney function trajectories before and after heart failure hospitalization in heart failure with reduced ejection fraction: findings from clinical trials and real-world data

来自临床试验和真实世界数据的试验结果：HFrEF患者在因心衰住院前后的肾功能变化轨迹

讲者：Nicolas Girerd

 

2.Sodium chloride vs. glucose solute as a volume replacement therapy for more effective decongestion in acute heart failure

氯化钠 vs 葡萄糖，作为容量替代疗法在急性心衰减充血治疗中的疗效对比

讲者：Jan Biegus

 

3.Combination oral acetazolamide and intravenous furosemide on acute decompensated heart failure

口服乙酰唑胺联合静脉注射呋塞米在急性失代偿性心衰（ADHF）患者中的疗效

讲者：Inne Pratiwi Farissa

 

4.Impact of a urinary-sodium driven algorithm to optimize natriuresis in patients with ADHF: the FASTR trial

FASTR试验：基于尿钠的算法对优化ADHF患者尿钠排泄的影响

讲者：Kevin Damman

 

5.A multicenter, randomized, double-blind, placebo-controlled, parallel group study on the safety and efficacy of istaroxime for pre-cardiogenic shock

探究心源性休克前期患者进行伊司他肟治疗安全性和有效性的多中心、随机、双盲、安慰剂对照、平行试验

讲者：Jan Biegus

 

6.The effect of a switch in fluid management on health status in heart failure patients: a prespecified subanalysis of the FRESH-UP study

FRESH-UP试验的预设亚组分析：液体管理方式改变对心衰患者健康状况的影响

讲者：Job Herrmann

 

Clinical trials updates in medical therapy

药物治疗的临床研究更新

当地时间：5月19日13:45 ~14:45

 

1.Effects of finerenone on readmissions for heart failure: a prespecified secondary analysis of the FINEARTS-HF trial

FINEARTS-HF试验的预设次要分析：非奈利酮在改善心衰再住院方面的疗效

讲者：Ankeet Bhatt

 

2.Trade-off of risk and benefit of finerenone across the spectrum of kidney function in patients with heart failure with mildly reduced and preserved ejection fraction in the FINEARTS-HF trial

FINEARTS-HF试验中，对于肾功能不同的射血分数轻度降低或保留的心衰患者，使用非奈利酮的风险和获益权衡

讲者：Safia Chatur

 

3.Intravenous ferric carboxymaltose in heart failure with iron deficiency

静脉注射羧基麦芽糖铁治疗合并缺铁的心衰患者

讲者：Mahir Karakas

 

4.Efficacy of intravenous iron for the treatment of heart failure varies by method of meta-analysis: a Bayesian and frequentist reappraisal of the evidence

基于贝叶斯和频率论方法对相关证据的重新评估：静脉注射铁剂治疗心衰的疗效因荟萃分析方法的不同而有所差异

讲者：Alasdair Henderson

 

5.The effect of omecamtiv mecarbil on outcomes analysed using the win ratio: an exploratory analysis of GALACTIC-HF

GALACTIC-HF试验的探索性分析：使用胜率评估omecamtiv mecarbil对治疗结局的影响

讲者：Kieran Docherty

 

6.EMPEROR-Preserved: association of echocardiographic features of diastolic dysfunction with the clinical efficacy of empagliflozin in HFpEF

EMPEROR-Preserved试验：在HFpEF患者中，舒张功能障碍的超声心动图特征与恩格列净临床疗效的相关性

讲者：Andrew Stewart Coats

 

Latest registries and observational studies

最新注册和观察性试验

当地时间：5月20日 08:30 ~09:30

 

1.Treatment uptake in the era of quadruple pharmacotherapy for heart failure with reduced ejection fraction: from prescriptions to patient adherence and persistence

在HFrEF四联药物治疗时代，从处方开具起患者的用药依从性和持续性

讲者：Felix Lindberg

 

2.Improvements in medical therapy and prognosis for patients with HFrEF following the 2021 ESC HF Guidelines: a nationwide registry study

一项全国性注册试验：根据2021 ESC HF指南，HFrEF患者的药物治疗和预后改善情况

讲者：Kristian Berge

 

3.Contemporary patient characterization and implementation of medical therapy for heart failure across the ejection fraction spectrum: the OPTIPHARM-HF registry

OPTIPHARM-HF注册试验：全射血分数谱心衰患者的当代特征描述及药物治疗实施情况

讲者：Riccardo Maria Inciardi

 

4.Timing of cardiac resynchronization therapy after optimal medical therapy in patients with heart failure: temporal trends, predictors and association with outcomes

行最佳药物治疗的心衰患者进行心脏再同步化治疗的时机：时间趋势、预测因素及与治疗结局的相关性

讲者：Alessandro Villaschi

 

5.Cardiac resynchronization therapy in heart failure: a target trial emulation study

一项目标仿真试验：心衰患者进行心脏再同步化治疗的疗效

讲者：Christian Basile

 

6.The MagMa study - detection of myocarditis through quantum technology

MagMa试验：通过量子技术检测心肌炎

讲者：Bettina Heidecker

 

信源：ESC-HFA 官网

(本网站所有内容，凡注明来源为“医脉通”，版权均归医脉通所有，未经授权，任何媒体、网站或个人不得转载，否则将追究法律责任，授权转载时须注明“来源：医脉通”。本网注明来源为其他媒体的内容为转载，转载仅作观点分享，版权归原作者所有，如有侵犯版权，请及时联系我们。)